# Keros Therapeutics, Inc.: Phase 2 study started recruiting, 36 planned (Duchenne Muscular Dystrophy)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Keros Therapeutics, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy |
| NCT ID | NCT07704099 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Duchenne Muscular Dystrophy |
| Intervention types | drug |
| Target enrollment | 36 |
| Site countries | New Zealand |
| Posted | 2026-07-15 |
| Planned start | 2026-09-25 |
| Event | Started recruiting |
| Event date | 2026-09-25 |
| Last update posted | 2026-09-30 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07704099). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.